No Data
No Data
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?
Wednesday Ends With Index Decline | Wall Street Today
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
No Data
No Data